Dupixent is the first and only biologic ... Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 2/3), eosinophilic esophagitis (Phase 3), chronic obstructive pulmonary disease ...

Sanofi and Regeneron’s Dupixent has already transformed the treatment of moderate-to-severe atopic dermatitis since it was first approved in 2017 – but it seems the IL-4 and IL-13 inhibitor ...

Dupixent (dupilumab) was the first biologic treatment approved for atopic dermatitis. It became available in 2017. It is currently approved for adults and adolescents 6 months and older with ...

Dupixent is a brand-name injection that doctors prescribe to treat certain conditions, including atopic dermatitis and asthma. Injection site reactions, such as pain, are common side effects of ...

Over the next 10 years, GlobalData has predicted that Dupixent will remain the most prescribed biologic therapy for atopic dermatitis, with global sales of $5.3 billion in 2027.

Dupilumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Unspecified Respiratory Disorders.

For some people, keeping up with eczema treatments can be difficult, but resources are available to help find relief from the ...

Why it matters: The approval marks an important milestone for this novel biologic drug given that the atopic dermatitis ... is currently approved—Dupixent, marketed by Sanofi) and the number ...